Novartis and the University of Pennsylvania signed an exclusive global research and licensing partnership that aims to accelerate the commercialization of CAR T-cell cancer therapies.
No takes yet. Share an insight, caveat, or question.
A 2012 study studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: